It’s starting to feel like Teva can’t catch a break.
It’s starting to feel like Teva can’t catch a break. After an incredibly rough series of events that led to massive layoffs, restructuring, and political upheaval, now Teva has quietly signaled to investors that the launch of its CGRP migraine med could be delayed.
